



Royal College
of Surgeons
of England
ADVANCING SURGICAL CARE

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



NHS
England



HQIP
Healthcare Quality
Improvement Partnership



NDRS
NATIONAL DISEASE REGISTRATION SERVICE



GIG
CYMRU
NHS
WALES

Rhwydwaith
Canser Cymru
Wales Cancer
Network



NATCAN
National Cancer Audit
Collaborating Centre

Longitudinal Trends in Androgen Receptor Pathway Inhibitor Prescribing for Metastatic Prostate Cancer in England Between 2013-2025 Using Real-World Data from the NHS England Prior Approval System

Justin KH Liu^{1,2}, Adrian Cook¹, Joanna Dodkins^{1,2}, Emily Mayne¹, Arjun Nathan^{1,2}, Julie Nossiter^{1,2}, Marina A Parry¹, Sugeeta Sukumar^{1,2}, Robert Fernley³, Jonathan Hill³, Giuseppe L Banna^{4,5}, Matthew G Parry^{1,6}, Alison C Tree⁷, Noel W Clarke^{8,9}, Jan van der Meulen²

¹National Cancer Audit Collaborating Centre (NATCAN), Clinical Effectiveness Unit (CEU), Royal College of Surgeons of England, London, UK; ²Department of Health Services Research and Policy, Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine (LSHTM), London, UK; ³Medicines Negotiation and Managed Access, Medicines Value and Access, NHS England, London, UK; ⁴Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK; ⁵Faculty of Science and Health, School of Medicine, Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK; ⁶Research Department of Targeted Intervention, Division of Surgery & Interventional Science, Faculty of Medical Sciences, University College London (UCL), London, UK; ⁷The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK; ⁸The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK; ⁹Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

INTRODUCTION

- Androgen Receptor Pathway Inhibitors (ARPIs) are a standard of care in first-line systemic treatment intensification of metastatic hormone-sensitive (mHSPC) and metastatic castrate-resistant (mCRPC) prostate cancer, but national prescribing trends over time remain incompletely described.
- Data from the NHS England Prior Approval System (NHSE PAS), currently provided by Blueteq, represents a novel independent data source which captures treatment approvals of high-cost cancer drugs across multiple tumour types.
- We used aggregate-level data from the NHSE PAS to assess temporal patterns of ARPI prescribing in England between 2013-2025.

METHODS

- Datasets were obtained via request from the Medicines Value and Access function, NHSE.
- Data items comprised: ARPI subtype (Abiraterone, Apalutamide, Darolutamide, Enzalutamide), year (quarters), disease setting (mHSPC vs mCRPC) and age (<75 years vs ≥75 years).
- Data points of less than 10 were suppressed to avoid patient identification.

RESULTS

68,039 ARPI approvals were identified in the NHSE PAS between 2013-2025.




Figure 1: Index Counts of ARPI approvals by disease setting between 2013-2025.

Between 2022-2025, ARPI approvals increased by ~60% for mHSPC and decreased by ~40% for mCRPC (**Figure 1**).

RESULTS




Figure 2: Relative proportion and number of ARPI approvals by age group (<75 vs ≥75) in the mHSPC (a) and mCRPC (b) settings.

In mHSPC, greater use of triplet therapy was observed in patients <75 between 2023-2025 in those who received an ARPI (28% vs 9% in 2025) (**Figure 2a**). In mCRPC, the utilisation of ARPIs pre-chemotherapy was greater compared to ARPIs post-chemotherapy across the study period, particularly in patients ≥75 (**Figure 2b**).

CONCLUSIONS

- The NHSE PAS provides a novel tool to describe the evolving trends in ARPI prescribing in different disease settings.
- These trends reflect the evolving patterns of ARPI utilisation across time, consistent with clinical trials evidence and approval of ARPIs in routine clinical practice.
- Age-related differences are also observed which has potential implications for systemic treatment sequencing, particularly in older patients.

Abstract code: IUC26597-94